Highest-materiality recent filing
Milestone Scientific 2026 annual meeting results: board elected, share authorization increased
Stockholders elected five incumbent directors: Casamento, Goldman, Hines, Demesmin, Sayed to serve until 2027 annual meeting.
Directors convert $466k in bridge notes to common stock, contingent on $0.50/share price
Holders Benedetta Casamento, Dr. Didier Demesmin, and Neal Goldman submitted conversion notices on July 24, 2026.
Milestone Scientific appoints two independent directors and names new Executive Chairman
Benedetta Casamento transitions from Board Chair to Executive Chairman, receiving $75,000 annual salary and $100,000 restricted stock grant.
Milestone Scientific reprices CEO & SVP options and proposes PRSU plan with up to 17.2M shares
CEO Eric Hines and SVP Jason Papes surrender options at $0.46-$0.50 for new options at $0.31 exercise price.
Milestone Scientific dismisses auditor CBIZ; engages Grassi & Co. effective May 15, 2026
CBIZ CPAs' 2025 audit report included a going concern explanatory paragraph about substantial doubt.
Milestone Scientific closes $2.15M private placement of units at $0.27/unit
Issued 7,962,963 units, each consisting of one common share and one warrant (exercise $0.3375, 3-yr term).
Milestone Scientific amends MOU with Innovest/BP4, extends lock-up deadline to April 17, 2026
Amendment extends deadline for BP4 lock-up agreements to April 17, 2026, with automatic extension to May 1 if a capital raise is underway.
Milestone Scientific increases authorized common shares from 100M to 125M
Certificate of Amendment filed with Delaware Secretary of State on March 10, 2026, effective upon filing.
MLSS enters amended MoU locking up ~8.9M BP4 shares for 12 months post-$2.5M qualified offering
BP4 (controlled by Innovest) agrees to lock up ~8.9M shares of MLSS for 12 months after a Qualified Offering raising at least $2.5M.
Milestone Scientific enters lock-up agreement with 11.31% shareholder BP4 after $2.5M offering
BP4 S.r.l., holder of 11.31% of MLSS common stock, agrees to 12-month lock-up after $2.5M offering.
All six incumbent directors re-elected with average 92.84% votes for; Benedicta Casamento got 85.92%.
Director Leonard A. Osser resigns from board, remains employed and consulting
Leonard A. Osser resigned as director effective November 7, 2025.
Milestone Scientific receives NYSE American delisting notice for non-compliance
Received NYSE American letter on Oct 8, 2025, citing non-compliance with Sections 1003(a)(ii) and (iii) of the Company Guide.
Milestone Scientific appoints Eric Hines as CEO; compensation includes options for 2M shares
Eric Hines named President and CEO effective July 31, 2025; also appointed to the Board.
Milestone Scientific appoints Shanth Thiyagalingam as independent director
Appointed on May 14, 2025 as an independent director; fills Board vacancy.
Milestone Scientific replaces auditor Marcum LLP with CBIZ CPAs P.C.
Marcum LLP resigned effective April 22, 2025; CBIZ CPAs P.C. engaged for FY ending Dec 31, 2025.
Director Giandomenico Trombetta resigns from Milestone Scientific board
Giandomenico Trombetta resigned as director effective January 12, 2025, citing personal reasons and immediate matters.
Milestone Scientific finalizes consulting agreement with ex-CEO Arjan Haverhals
Consulting agreement with RH Consulting LLC effective Jan 1, 2025, for indefinite term.
CEO Arjan Haverhals retires as officer on Dec 31, 2024; remains director and consultant through family company.
Milestone Scientific posts investor presentation on Sep 27; details not in filing
Investor presentation made available on company website on September 27, 2024.
Milestone Scientific annual meeting elects all directors, ratifies auditors
All seven incumbent directors elected with at least 30 million shares for each; broker non-votes 20.4 million on each.
Milestone Scientific nets $1.98M from selling NOLs and R&D credits to Comcast
Received net $1,983,095 from Comcast Corporation on April 8, 2024 for unused NOLs and R&D tax credits.
Milestone Scientific underwriter exercises overallotment, raising $216,847
Maxim Group exercised overallotment for 372,110 shares at $0.63 per share on Jan 12, 2024.
Milestone Scientific prices $3M public offering of 4.765M shares at $0.63 per share
Offering of 4,765,000 common shares at $0.63/share; gross proceeds ~$3.0 million.
Milestone Scientific appoints Dr. Didier Demesmin as independent director
Appointed September 6, 2023 as independent director by unanimous board vote.
Milestone Scientific CFO Peter J. Milligan resigns effective Sept 1, 2023
CFO Peter J. Milligan resigns effective September 1, 2023, citing decision to pursue other opportunities.
Amendment extends severance period for CEO Arjan Haverhals from six months to two years upon qualifying termination.
All six incumbent directors re-elected: Neal Goldman 15.3M for, Leonard Osser 14.96M for, others similarly.
Milestone Scientific appoints Peter Milligan as part-time CFO effective Feb 1, 2023
Annual salary of $120,000 plus incentive bonus target of 40% of cash compensation payable in shares.
Director Leslie Bernhard resigns; Neal Goldman named Chairman; CEO Arjan Haverhals joins board
Leslie Bernhard resigned as director, Audit Committee Chair, and Board Chair after 20 years; no disagreement cited.
Director Leonard M. Schiller resigns from Milestone Scientific board after 26 years
Leonard M. Schiller resigned as director on December 5, 2022.
Milestone Scientific dismisses Friedman LLP, appoints Marcum as auditor after merger
Audit committee approved dismissal of Friedman LLP and engagement of Marcum LLP effective October 13, 2022.
All seven incumbent directors elected; votes for ranged from 27.6M to 28.2M; broker non-votes ~18.1M each.
Milestone Scientific appoints Benedetta Casamento to Board of Directors
Benedetta Casamento appointed to the Board effective April 27, 2022.
Milestone Scientific reports >$14M cash at end of 2021, liquidity for 2 years
Cash and equivalents exceeded $14M at Dec 31, 2021, equivalent to year-end 2020.
Milestone director adopts 10b5-1 plan to sell ~$1M stock at $20k/week
Board member and former CEO Leonard Osser adopts Rule 10b5-1 trading plan effective December 13, 2021.
Milestone Scientific CFO Scott Kahn departs; search underway for replacement
Scott Kahn and company mutually agreed to part ways effective July 2, 2021.
On June 19, 2026, the Board of Directors of the Company unanimously appointed, by the directors in attendance, Kelly Ulto and Greg Shilling as independent directors of the Company.
On June 19, 2026, the Board of Directors of the Company unanimously appointed, by the directors in attendance, Kelly Ulto and Greg Shilling as independent directors of the Company.
Shanth Thiyagalingam, a member of the Board of Directors (the “Board”) since 2025, was nominated to continue as a director but has advised the Company that he has decided to devote his full time as chief executive officer of PainTEQ and to his family, and not to run for re-election.
electing Ms. Casamento as Executive Chairman.
On May 14, 2025, the Board of Directors of Milestone Scientific Inc. (the “Company”) unanimously by the directors in attendance appointed Shanth Thiyagalingam as an independent director of the Company.
On January 12, 2025, Mr. Giandomenico Trombetta, a director of Milestone Scientific Inc. (the “Company”), advised the Chairman of the Board that he is resigning, effective immediately, as a director.
Mr. Neal Goldman, the Chairman of the Board of Directors of the Company, has been appointed the Interim Chief Executive Officer, effective on Mr. Haverhals retirement.
On November 8, 2024, Mr. Arjan Haverhals, the Chief Executive Officer of Milestone Scientific Inc. (the “Company”), advised the Chairman of the Board that he intends to retire as an officer from the Company upon the expiration of, and not seek the renewal of, his employment agreement, on December 31, 2024.
On September 6, 2023, the Board of Directors of Milestone Scientific Inc. (the “Company”) unanimously by the directors in attendance appointed Dr. Didier Demesmin as an independent director of the Company.
On August 24, 2023, Milestone Scientific Inc. (the “Company”) announced that Peter J. Milligan, the Company’s part-time Chief Financial Officer, resigned effective September 1, 2023.
On February 6, 2023, Milestone Scientific Inc. (the “Company”) announced the appointment of Peter Milligan as the Company’s Chief Financial Officer, on a part-time basis, effective February1, 2023.
On January 4, 2023, Leslie Bernhard tendered her resignation to Milestone Scientific Inc. (the "Company") as a director, Chairman of the Audit Committee and Chairman of the Board of the Company.
Max materiality 0.80 · Median 0.40 · Most common event other_material